
Using patient-derived CNS lymphoma (CNSL) slice cultures, this study evaluated ibrutinib’s effects on the tumor immune microenvironment. Despite low lymphoma infiltration (mean allele frequency 1.05–4.96%), key mutations (e.g., MYD88, CD79B) and immune-evasive CNAs were preserved. Single-nucleus RNA-seq highlighted ibrutinib-induced myeloid modulation, offering new insights into BTK inhibition in immune-privileged CNS sites—paving the way for targeted immunomodulatory strategies.
Like
Save
Share